Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SR57746A · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| SR57746A | DRUG | - |
Inclusion Criteria: * Histologically or cytologically proven adenocarcinoma of the colon or the rectum * age \> 18 years * WHO performance status : 0,1,2 * Signed written informed consent prior to study entry * Disease stage : metastatic disease not amenable to potentially curative treatment (eg : ...
SR57746A, also known as xaliproden, is an investigational small molecule being studied for its potential to reduce neurotoxicity in patients with metastatic colorectal cancer receiving oxaliplatin plus 5-FU/LV chemotherapy. It is in Phase 3 clinical development for this oncology indication.
SR57746A is a small molecule developed by Sanofi. Its specific molecular target has not been disclosed in available clinical trial information. The drug is being evaluated for its ability to reduce chemotherapy-induced neurotoxicity in patients with metastatic colorectal cancer.
SR57746A is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. The drug is currently in Phase 3 clinical development for reducing neurotoxicity associated with oxaliplatin-based chemotherapy in metastatic colorectal cancer.
SR57746A is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 3 trial has been completed to evaluate its efficacy in reducing neurotoxicity in patients with metastatic colorectal cancer receiving oxaliplatin plus 5-FU/LV chemotherapy.
SR57746A has been studied in one completed Phase 3 clinical trial, identified as NCT00272051. This trial, titled XENOX, evaluated the efficacy of xaliproden in reducing the neurotoxicity of oxaliplatin plus 5-FU/LV chemotherapy in 620 patients with metastatic colorectal cancer.
Yes, SR57746A is also known as xaliproden. The drug is being developed by Sanofi and has been investigated in a Phase 3 clinical trial for reducing neurotoxicity in patients with metastatic colorectal cancer receiving oxaliplatin-based chemotherapy.